This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
(all figures are in Canadian dollars unless otherwise noted)BELLEVILLE, ON,
Nov. 5, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of Fiscal 2014 (ended
September 30, 2013).
"I'm pleased to report that revenues from product sales in our Animal Health business unit increased by 17% in the first quarter of Fiscal 2014 as compared to the same period last year," said Mr.
Andrew Grant,President of Bioniche Animal Health (global). "The divestment of this business is being pursued by the Company and this revenue growth will be very encouraging to the potential purchasers."
As a result of the Company's decision to divest the Animal Health business, the Fiscal 2014 first quarter financial statements have been segmented into continuing operations (Human Health and One Health business units) and discontinued operations (Animal Health business unit).
Fiscal 2014 First Quarter Financial Results Highlights
The Company's continuing operations recorded no income in the quarter, as compared to
$0.07 million in the same period in Fiscal 2013. In Fiscal 2013, the Company received reimbursement from its former development partner for
Urocidin™-related development costs. Such reimbursement was discontinued when the Company regained global rights to
Urocidin™ in December, 2012.
Cash and cash equivalents from continuing operations amounted to
$15.9 million at
September 30, 2013, as compared to
$4.2 million at
June 30, 2013.
The Company's total liabilities and shareholders' equity at
September 30, 2013 is
$74.6 million, as compared to
$61.5 million at
June 30, 2013.
The Company's consolidated cash flow used in operations for the quarter ended
September 30, 2013 (both continuing and discontinued operations) was
($4.7) million, as compared to cash used in operations of
($5.0) million in Q1, Fiscal 2013. The average monthly burn rate (before changes in working capital) was
$1.3 million for Q1, Fiscal 2014, as compared to
$1.8 million for the same quarter in Fiscal 2013. Financial expenses are a substantial contributor to the Company's average monthly burn rate. These amounted to
$1.3 million for the first three months of Fiscal 2014 compared to
$0.8 million recorded in Q1, Fiscal 2013.
"The Company reduced expenditures by
$1.2 million in the first quarter as compared to the same period last year," said Mr.
Brian Ford, Chief Financial Officer of Bioniche Life Sciences Inc. "However, this reduction was offset by one-time legal and other expenditures related to the concerned shareholder activity of
Administration expenses for continuing operations were
$1.3 million in the first quarter of Fiscal 2014, as compared to
$1.7 million in the first quarter of Fiscal 2013. The decrease reflects the Company's continued efforts to reduce the burn rate. The Company also incurred expenses related to the aforementioned settlement expenditures. Marketing and selling expenses were steady at
$0.2 million in both comparative quarters.
Net research and development (R&D) expenditures for continuing operations were
$3.1 million in the first quarter of Fiscal 2014, as compared to
$3.2 million in Q1, Fiscal 2013. This includes the continued investment in the staffing and infrastructure associated with the GMP production of the Company's
Urocidin™ bladder cancer treatment that is in Phase III clinical development. As the validation process on the fermentor area of the Company's Vaccine Manufacturing Centre in
Belleville has been completed, the Company has begun to depreciate the facility. Until such time as the facility is fully validated and making commercial product, the carrying costs associated with this facility are being accounted for under R&D.
Additional R&D resources are focused on the advancement of a second generation
E. coli O157 cattle vaccine.
The basic and fully diluted net loss per share for the Company's continuing operations for Q1, Fiscal 2014 is
($0.07), as compared to a basic and fully diluted net loss per share of
($0.06) in Q1, Fiscal 2013.
Fiscal 2014 First Quarter Financial Results Highlights - Discontinued Operations (Animal Health)
In May, 2013, the Company formally commenced the process to divest its Animal Health business and concentrate on becoming a Human Health company. The divestment is proceeding well, with binding offers expected to be tendered before the end of the calendar year.